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Multi-drug resistance, inappropriate initial
antibiotic therapy and mortality in Gram-negative
severe sepsis and septic shock: a retrospective
cohort study
Marya D Zilberberg1,2*, Andrew F Shorr3, Scott T Micek4, Cristina Vazquez-Guillamet5 and Marin H Kollef6
Abstract
Introduction: The impact of in vitro resistance on initially appropriate antibiotic therapy (IAAT) remains unclear. We
elucidated the relationship between non-IAAT and mortality, and between IAAT and multi-drug resistance (MDR) in
sepsis due to Gram-negative bacteremia (GNS).
Methods: We conducted a single-center retrospective cohort study of adult intensive care unit patients with
bacteremia and severe sepsis/septic shock caused by a gram-negative (GN) organism. We identified the following
MDR pathogens: MDR P. aeruginosa, extended spectrum beta-lactamase and carbapenemase-producing organisms.
IAAT was defined as exposure within 24 hours of infection onset to antibiotics active against identified pathogens
based on in vitro susceptibility testing. We derived logistic regression models to examine a) predictors of hospital
mortality and b) impact of MDR on non-IAAT. Proportions are presented for categorical variables, and median values
with interquartile ranges (IQR) for continuous.
Results: Out of 1,064 patients with GNS, 351 (29.2%) did not survive hospitalization. Non-survivors were older
(66.5 (55, 73.5) versus 63 (53, 72) years, P = 0.036), sicker (Acute Physiology and Chronic Health Evaluation II (19 (15, 25)
versus 16 (12, 19), P <0.001), and more likely to be on pressors (odds ratio (OR) 2.79, 95% confidence interval (CI) 2.12
to 3.68), mechanically ventilated (OR 3.06, 95% CI 2.29 to 4.10) have MDR (10.0% versus 4.0%, P <0.001) and receive
non-IAAT (43.4% versus 14.6%, P <0.001). In a logistic regression model, non-IAAT was an independent predictor of
hospital mortality (adjusted OR 3.87, 95% CI 2.77 to 5.41). In a separate model, MDR was strongly associated with the
receipt of non-IAAT (adjusted OR 13.05, 95% CI 7.00 to 24.31).
Conclusions: MDR, an important determinant of non-IAAT, is associated with a three-fold increase in the risk of hospital
mortality. Given the paucity of therapies to cover GN MDRs, prevention and development of new agents are critical.
Introduction
Antimicrobial resistance is a growing challenge in the care
of critically ill patients, among whom the burden of infec-
tion remains high. Escalating rates of antibiotic resistance
add substantially to the morbidity, mortality, and cost
related to infection in the ICU [1]. Traditionally, most
efforts to understand issues of resistance and ICU out-
comes have addressed Gram-positive organisms, such as
methicillin-resistant Staphylococcus aureus [2,3]. However,
in the United States, alarming trends in resistance are now
also reported for a number of Gram-negative pathogens.
For example, extended-spectrum beta-lactamase (ESBL)
organisms are now endemic in many ICUs, and 15 to 20%
of all Pseudomonas aeruginosa isolates from serious in-
fections are categorized as multidrug resistant (MDR)
because of reduced in vitro susceptibility to three or more
classes of antibiotics [4-6]. Of even more concern are
pathogens for which clinicians have few antibiotic options,
namely Acinetobacter baumanii and carbepenemase-
producing Enterobacteriaceae (CPE) [4-6]. In the case
of these Gram-negative organisms, studies also point
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to an association between resistance and both clinical
and economic outcomes [1].
The mechanism for poor outcomes with resistant Gram-
negative organisms is not completely clear. In general, these
bacteria are not believed to be inherently more virulent
than similar susceptible species. Resistance and its rapid
evolution, however, make efforts to insure initially appro-
priate antibiotic therapy (IAAT) more difficult, and IAAT is
a key determinant of outcome in severe infection [7-10].
IAAT has consistently been shown to reduce mortality rates
in severe sepsis and septic shock, and the Surviving Sepsis
Campaign Guidelines strongly support initiatives to guaran-
tee that patients receive timely antibiotic treatment [11-16].
However, it remains unclear what proportion of IAAT is
driven by in vitro resistance. Appreciating this relationship
may facilitate efforts to improve outcomes by helping clini-
cians determine how to apply newer diagnostic modalities
and therapeutic options.
We sought to confirm the importance of IAAT in severe
sepsis and septic shock due to Gram-negative bacteria and
to estimate the impact of initially inappropriate antibiotic
therapy (non-IAAT) on mortality in these syndromes.
More importantly, we aimed to identify variables associ-
ated with IAAT and to elucidate the relationship between
IAAT and in vitro antimicrobial resistance. To accomplish
this we conducted a large retrospective analysis of sub-
jects with severe sepsis or septic shock and Gram-negative
bacteremia.
Materials and methods
Study design and ethical standards
We conducted a single-center retrospective cohort study
from January 2008 to December 2012. Barnes-Jewish Hos-
pital is a 1,200-bed urban academic medical center located
in St. Louis, MO, USA. The study was approved by the
Washington University School of Medicine Human Studies
Committee and informed consent was waived since the
data collection was retrospective without any patient-
identifying information. The study was performed in
accordance with the ethical standards of the 1964
Declaration of Helsinki and its later amendments.
Study cohort
All consecutive adult ICU patients between January
2008 and December 2012 were included if: they had a
positive blood culture for a Gram-negative organism;
and there was an International Classification of Diseases,
Version 9, Clinical Modification (ICD-9-CM) code cor-
responding to an acute organ dysfunction [17]. Only the
first episode of sepsis was included.
Definitions
To be included in the analysis, patients had to meet cri-
teria for severe sepsis based on discharge ICD-9-CM
codes for acute organ dysfunction [17]. Patients were
classified as having septic shock if vasopressors (nor-
epinephrine, dopamine, epinephrine, phenylephrine, or
vasopressin) were initiated within 24 hours of the blood
culture collection date and time. Antimicrobial treat-
ment was deemed IAAT if the initially prescribed anti-
biotic regimen was active against the identified pathogen
based on in vitro susceptibility testing and was adminis-
tered within 24 hours following blood culture collection.
Combination therapy was not required to be considered
IAAT. We also required that antibiotics had to be pre-
scribed for at least 24 hours. All other regimens were
classified as non-IAAT. Prior antibiotic exposure was any
exposure to an antibiotic within the preceding 90 days.
Combination antimicrobial treatment was not required
for IAAT designation. This is supported by multiple stud-
ies indicating that while dual therapy is more likely than
single therapy to result in appropriate coverage, it is not
necessarily associated with better outcomes provided the
organism is adequately covered by a single drug [18]. We
utilized the same time frame (90 days prior to the onset of
the current episode of bacteremia) to define prior hospita-
lization. In contrast, prior bacteremia was defined by a
bacteremia that had occurred within 30 days of the current
episode. Multidrug-resistant P. aeruginosa (MDR-PA) was
defined as P. aeruginosa resistant to at least three of the
following classes of antimicrobials: aminoglycosides,
anti-pseudomonal penicillins, anti-pseudomonal cepha-
losporins, carbapenems, and fluoroquinolones. A case
was classified as MDR if the blood culture was positive
for a MDR-PA, an ESBL organism, or a CPE. Both ESBL
and CPE status were established based on molecular
laboratory testing.
Antimicrobial treatment algorithms
From January 2002 through to the present, Barnes-Jewish
Hospital utilized an antibiotic control program to help
guide antimicrobial therapy. During this time cefepime,
gentamicin, vancomycin, or fluconazole use was unre-
stricted. However, initiation of ciprofloxacin, imipenem,
meropenem, piperacillin/tazobactam, linezolid, daptomy-
cin, or micafungin was restricted and required preautho-
rization from a clinical pharmacist or infectious diseases
physician. Each ICU had a clinical pharmacist who re-
viewed antibiotic orders to ensure that dosing and the
interval of administration were adequate for patients
based on body size, renal function, and resuscitation sta-
tus. After daytime hours the on-call clinical pharmacist
reviewed and approved the antibiotic orders. The initial
antibiotic dosages employed for treatment were as follows:
cefepime, 1 to 2 g every 8 hours; piperacillin-tazobactam,
4.5 g every 6 hours; imipenem, 0.5 g every 6 hours; mero-
penem, 1 g every 8 hours; ciprofloxacin, 400 mg every 8
hours; gentamicin, 5 mg/kg once daily; vancomycin, 15
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mg/kg every 12 hours; linezolid, 600 mg every 12 hours;
daptomycin, 6 mg/kg every 24 hours; fluconazole, 800 mg
on the first day followed by 400 mg daily; and micafungin,
100 mg daily.
Starting in June 2005, with regular updates, a sepsis
order set was implemented in the emergency department,
general wards, and the ICUs with the intent of standar-
dizing empiric antibiotic selection for patients with sepsis
based on the infection type (i.e. community-acquired pneu-
monia, healthcare-associated pneumonia, intra-abdominal
infection, and so forth) and the hospital’s antibiogram.
However, antimicrobial selection, dosing, and de-escalation
of therapy were still optimized by clinical pharmacists in
these clinical areas.
Antimicrobial susceptibility testing
The microbiology laboratory performed antimicrobial sus-
ceptibility of the Gram-negative blood isolates using the
disk diffusion method according to guidelines and break-
points established by the Clinical Laboratory and Standards
Institute and published during the inclusive years of the
study [19,20].
Data elements
Patient-specific baseline characteristics and process of care
variables were collected from the automated hospital
medical record, microbiology database, and pharmacy
database of Barnes-Jewish Hospital. Electronic inpatient
and outpatient medical records available for all patients in
the BJC Healthcare system were reviewed to determine
prior antibiotic exposure. The baseline characteristics
collected included: age, gender, race, past history of con-
gestive heart failure, chronic obstructive pulmonary dis-
ease, diabetes mellitus, chronic liver disease, underlying
malignancy, and end-stage renal disease requiring dialysis.
The comorbidities were identified based on their cor-
responding ICD-9-CM codes. The Acute Physiology and
Chronic Health Evaluation II and Charlson comorbidity
scores were calculated based on clinical data present dur-
ing the 24 hours after the positive blood cultures were
obtained [21]. This was done to accommodate patients
with community-acquired and healthcare-associated
community-onset infections who only had clinical data
available after blood cultures were drawn. Healthcare-
associated infections were defined by the presence of at
least one of the following risk factors: recent hospita-
lization (within 90 days of the current one); immune sup-
pression; nursing home residence; hemodialysis; and prior
antibiotics (within 90 days of the current hospitalization).
The primary outcome variable was hospital mortality.
Because we were interested in understanding the con-
tribution of MDR pathogens to the risk of receiving non-
IAAT, we examined this variable as a secondary endpoint
in a logistic regression.
Statistical analyses
Continuous variables were reported as means with stand-
ard deviations and as medians with 25th and 75th per-
centiles. Differences between mean values were tested via
the Student’s t test, while those between medians were
examined using the Mann–Whitney U test. Categorical
data were summarized as proportions, and the chi-square
test or Fisher’s exact test for small samples was used to
examine differences between groups. We developed sev-
eral multiple logistic regression models to identify clinical
risk factors that were associated with hospital mortality.
In the mortality models, all risk factors that were sig-
nificant at ≤0.20 in the univariate analyses, as well as
all biologically plausible factors even if they did not
reach this level of significance, were included in the
corresponding multivariable analyses. All variables en-
tered into the models were examined to assess for co-
linearity, and interaction terms were tested. The most
parsimonious models were derived using the back-
ward manual elimination method, and the best-fitting
model was chosen based on the area under the receiver
operating characteristics curve (c statistic). The model’s
calibration was assessed with the Hosmer–Lemeshow
goodness-of-fit test. Similarly, the most parsimonious
model for the predictors of inappropriate empiric anti-
biotic was computed and its fit was tested with the c stat-
istic and the Hosmer–Lemeshow goodness of fit. All tests
were two tailed, and P <0.05 was deemed a priori to repre-
sent statistical significance.
All computations were performed in Stata/SE, version 9
(StataCorp, College Station, TX, USA).
Results
In total, 1,076 patients with severe sepsis or septic shock
due to a Gram-negative pathogen met the inclusion
criteria. The distribution of the pathogens is presented in
Table 1. Among these 1,076 culture-positive cases, there
were 63 (5.9%) cultures that met the MDR criteria (Table 1).
The most common MDR organism was MDR-PA, ac-
counting for 15.0% of all P. aeruginosa isolates.
Among the 1,064 patients whose hospital disposition
was known, 311 (29.2%) died in the hospital. Their base-
line characteristics are presented in Table 2. Patients
who died were older, less likely to be admitted from
home, and had a higher comorbidity burden than those
who survived their hospitalization, as signified by the
Charlson comorbidity score. A higher proportion of those
patients who died prior to discharge (95.7%) had a risk
factor for a healthcare-associated infection than those
who were discharged alive (91.4%, P = 0.014).
In the run-up to and at the time of sepsis onset, pa-
tients who did not survive had a slightly longer presepsis
hospital length of stay, although this difference did not
meet the predetermined level of statistical significance
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(Table 2). Several healthcare-associated factors (hemo-
dialysis, prior hospitalization, and antibiotics) were more
prevalent among nonsurvivors. However, the vast major-
ity of the cohort (over 90%) had at least one healthcare-
associated risk factor (Table 2). Additionally, survivors
had a higher frequency of having had surgery during the
index hospitalization than those who died. All markers
of severity of acute illness were higher in patients who
died compared with those who survived; the Acute
Physiology and Chronic Health Evaluation II score was
higher, and septic shock and the need for mechanical
ventilation were significantly more prevalent among
nonsurvivors than among survivors (Table 2, Figure 1).
Urine and an infected line were less likely sources of in-
fection and the lung was more likely as a source of infec-
tion among nonsurvivors compared with survivors.
There were also striking differences between the two
groups in terms of the likelihood of a MDR pathogen
as the sepsis culprit (10.0% among nonsurvivors vs.
4.0% among survivors, P <0.001) (Figure 1). Additionally,
nonsurvivors were approximately three times more likely
to receive non-IAAT than those patients who survived
their hospitalization (43.4% vs. 14.6%, P <0.001) (Figure 1).
Among the 245 patients who received non-IAAT, resist-
ance to instituted empiric therapy was far more prevalent
as a reason (75.5%) than delay in treatment (24.5%). When
stratified by hospital death, the relationship generally held,
although delay in treatment was slightly more likely
among those who died (28.9%) than those who survived
their hospitalization (19.1%, P = 0.076). Similarly, delay in
therapy accounted for a minority of non-IAAT among pa-
tients with a MDR pathogen (25.5%), with a nearly identi-
cal frequency of delay observed among those without a
MDR pathogen (23.8%, P = 0.798).
Multiple logistic regression models were constructed
and tested for fit, with the factors presented in Table 3
having the best discrimination. In this model, as in others
that included this model, receiving non-IAAT was the
strongest predictor of hospital death with an adjusted
odds ratio of 3.87 (95% confidence interval = 2.77 to 5.41,
P <0.001, c statistic = 0.777).
When focusing on the choice of empiric treatment
among patients with a MDR pathogen versus those with-
out, the unadjusted odds ratio of receiving non-IAAT was
11.79 (95% confidence interval = 6.55 to 21.23, P <0.001).
In a logistic regression model to examine the factors that
contribute to this inappropriate choice of therapy, a MDR
pathogen as the etiology of sepsis was the strongest pre-
dictor of inappropriate treatment with an adjusted odds
ratio of 13.05 (95% confidence interval = 7.00 to 24.31,
P < 0.001, c statistic = 0.738) (Table 4). This parameter
had by far the highest odds of any variable retained in the
model of predictors of non-IAAT. (Tables 5, 6 and 7 present
the details of characteristics based on appropriateness of
Table 1 Microbiology of Gram-negative severe sepsis and septic shock
All organisms MDR-PA ESBL CP Total MDR
N % N % N % N % N %
Pseudomonas aeruginosaa 173 16.08 26 15.03 1 0.58 1 0.58
Acinetobacter spp.b 73 6.78 1 1.37 1 1.37
Bacteroides spp. 83 7.71
Stenotrophomonas maltophilia 22 2.04
Enterobacteriaceae
Klebsiella pneumoniaec 217 20.17 13 5.99 8 3.69
Escherichia coli 284 26.39 14 4.93
Klebsiella oxytoca 35 3.25 3 8.57
Proteus mirabilis 55 5.11
Serratia marcescens 46 4.28
Citrobacter freundii 25 2.32
Enterobacter aerogenes 35 3.25
Enterobacter cloacae 90 8.36 1 1.11
Otherd 6 0.56
Polymicrobial 191 17.75
Total 1,076 100.00 26 33e 10 63f 5.86
CP, carbapenemase-producing; ESBL, extended-spectrum beta lactamase; MDR, multidrug resistant; MDR-PA, multidrug resistant P. aeruginosa. aSame MDR-PA
specimen that was positive for both ESBL and CP. bSame Acinetobacter baumanii specimen that was positive for both ESBL and CP. cTwo patients each had one
CP K. pneumoniae + one ESBL K. pneumoniae. dAeromonas sobria (n = 2), Haemophilis influenza (n = 2), Pseudomonas putida (n = 1), Achromobacter sp. (n = 1). eThese
33 specimens came from 32 patients (one patient had 2 ESBL organisms: E. coli and K. pneumoniae). fThe six-sample discrepancy is explained by the above overlaps,
and one patient has ESBL E. coli and CP K. pneumoniae.
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Table 2 Baseline and infection characteristics and outcomes
Died (n = 311) Survived (n = 753) P value
N % N %
Baseline characteristics
Age (years)
Mean ± standard deviation 65.0 ± 13.0 62.3 ± 14.8
Median (25th, 75th percentiles) 66.5 (55, 73.5) 63 (53, 72) 0.036
Race
Caucasian 198 63.67 504 66.93 0.101
African-American 96 30.87 193 25.63
Hispanic 0 0.00 1 0.13
Other 1 0.32 8 1.06
Unknown 10 3.22 41 5.44
Asian 6 1.93 6 0.80
Sex, female 140 45.60 356 47.34 0.518
Admission source
Home 178 57.23 530 70.48 0.001
Nursing home/LTAC 30 9.65 62 8.24
Transfer from other hospital 88 28.30 143 19.02
Unknown 14 4.50 14 1.86
Other 1 0.13 3 0.40
Comorbidities
CHF 78 25.08 136 18.06 0.009
COPD 92 29.58 171 22.71 0.018
CLD 65 20.90 105 13.94 0.005
DM 79 25.40 195 25.90 0.867
CKD 68 21.86 126 16.73 0.049
Malignancy 128 41.16 340 45.15 0.232
HIV 6 1.93 6 0.80 0.112
Charlson comorbidity score
Mean ± standard deviation 5.4 ± 3.6 4.9 ± 3.3
Median (25th, 75th percentiles) 5 (3, 8) 4 (2, 7) 0.022
HCA risk factors 292 95.74 676 91.35 0.014
Hemodialysis 41 13.62 52 6.92 0.001
Immune suppression 134 44.08 290 39.30 0.153
Prior hospitalization 204 69.86 445 62.06 0.019
Nursing home residence 30 9.65 62 8.23 0.456
Prior antibiotics 194 62.38 405 53.78 0.010
Hospital-acquired BSIa 153 49.20 350 46.48 0.420
Bacteremia that was not HCA (that is, community acquired) 19 6.11 77 10.23 0.033
Prior bacteremia within 30 days 37 11.90 97 12.88 0.660
Sepsis characteristics and outcomes
LOS prior to sepsis onset, days
Mean ± standard deviation 9.8 ± 18.4 7.3 ± 12.1
Median (25th, 75th percentiles) 2 (0, 13) 1 (0, 11) 0.227
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treatment, as well as an alternative model for the pre-
dictors of non-IAAT. See Table 7 footnote for a brief
discussion of that model.)
Discussion
This large retrospective analysis confirms that non-IAAT
is a key determinant of short-term mortality among
patients with severe sepsis and septic shock due to a
Gram-negative organism. More importantly, our findings
indicate that the presence of a MDR Gram-negative pa-
thogen is strongly associated with non-IAAT. Despite the
relatively low prevalence of a MDR phenotype among all
subjects with Gram-negative bacteremia, these patho-
gens exert an excessive impact on mortality. In other
words, MDR pathogens disproportionately affect outcomes
through an intermediate step as it relates to antibiotic ther-
apy. In light of the increasing frequency of multidrug
resistance, our observations suggest that urgent action is
needed to prevent potential escalation of mortality rates in
severe sepsis and septic shock.
Because the co-occurrence of MDR pathogens and
non-IAAT was relatively rare, it is important to consider
the context of total non-IAAT exposure. The pool for
the MDR pathogens as defined in our study comprises the
vast majority of Gram-negative organisms responsible for
serious infections in the ICU. That is, compared with
Acinetobacter spp., for example, the relative prevalence of
P. aeruginosa and Enterobacteriaceae was an order of mag-
nitude higher. Epidemiologically, this imbalance makes it
imperative for clinicians to consider these organisms first
and foremost when choosing empiric treatment. We have
demonstrated that multidrug resistance among these
organisms comprises one important mechanism for errors
in empiric coverage. At the same time, Acinetobacter spp.
and Stenotrophomonas maltophilia infections, although
a minority, were extremely likely to be subject to
Table 2 Baseline and infection characteristics and outcomes (Continued)
Surgery
None 227 73.94 510 68.36 0.011
Abdominal 38 12.38 150 20.11
Extra-abdominal 42 13.68 86 11.53
Central line 199 67.46 462 63.55 0.236
Total parenteral nutrition 19 6.33 56 7.53 0.499
APACHE II score
Mean ± standard deviation 19.9 ± 7.4 15.8 ± 5.4
Median (25th, 75th percentiles) 19 (15, 25) 16 (12, 19) <0.001
Peak WBC
Mean ± standard deviation 21.6 ± 18.7 22.6 ± 17.7
Median (25th, 75th percentiles) 16.4 (7.2, 32) 18.0 (8.2, 37) 0.275
Infection sourceb
Urine 60 19.29 201 26.69 0.011
Abdomen 49 15.76 106 14.08 0.48
Lung 88 28.30 129 17.13 <0.001
Line 23 7.40 86 11.42 0.049
CNS 4 1.29 3 0.40 0.204
Skin 20 6.43 42 5.58 0.589
Unknown 90 28.94 241 32.01 0.326
Polymicrobal 60 19.29 129 17.13 0.402
Total hospital LOS (days)
Mean ± standard deviation 22.9 ± 28.3 23.3 ± 23.7
Median (25th, 75th percentiles) 15 (6, 28) 17 (8, 30) 0.013
Hospital LOS following sepsis onset, days
Mean ± standard deviation 13.1 ± 19.8 16.0 ± 18.0
Median (25, 75) 8 (3, 17) 10 (6, 20) <0.001
APACHE, Acute Physiology and Chronic Health Evaluation; BSI, bloodstream infection; CHF, congestive heart failure; CKD, chronic kidney disease; CNS, central
nervous system; COPD, chronic obstructive pulmonary disease; CLD, chronic liver disease; DM, diabetes mellitus; HCA, healthcare-associated; LOS, length of stay;
LTAC, long-term acute care; WBC, white blood cells. aHospital-acquired BSI defined as BSI that developed after day 2 of hospitalization. bMultiple sources possible.
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inappropriate empiric treatment (Table 6). Because
the risk for drug resistance is very high among these
organisms, the observed elevated rates of non-IAAT
are probably not because the clinician did not consider
their risk for resistance, but rather due to his/her deter-
mination that these were not likely pathogens. This ap-
proach therefore represents a slightly different mechanism
for causing non-IAAT and implies a different solution.
Rather than understanding the antibiogram of common
pathogens, this requires a clinician to be aware of the rates
of specific less common organisms at his/her institution.
An additional important mechanism for receiving non-
IAAT exists based on the timing of empiric therapy.
Fully one-quarter of all non-IAAT fell into this category
















Figure 1 Sepsis severity, resistance and initial treatment. IAAT, initially appropriate antibiotic therapy; MDR, multidrug resistant. P <0.001 for
each comparison.
Table 3 Predictors of hospital mortalitya
Odds ratio 95% confidence
interval
P value
Non-IAAT 3.872 2.770 to 5.413 <0.001
Chronic liver disease 1.942 1.319 to 2.860 0.001
Septic shock 1.846 1.335 to 2.553 <0.001
Pneumonia 1.766 1.237 to 2.522 0.002
Mechanical ventilation 1.669 1.172 to 2.376 0.005
APACHE II score (per 1 point) 1.076 1.047 to 1.105 <0.001
Surgery 0.701 0.560 to 0.879 0.002
Admitted from home 0.677 0.489 to 0.936 0.018
Urosepsis 0.675 0.469 to 0.972 0.034
aIndependent variables included but not retained in the model at alpha ≤0.05:
age, race, admission sources other than home (nursing home or transfer from
another facility), comorbidities of congestive heart failure, chronic obstructive
pulmonary disease, chronic kidney disease and human immune deficiency
virus infection, Charlson comorbidity score, healthcare-associated infection risk
factors (hemodialysis, immune suppression, prior hospitalization, prior antibiotics),
mechanical ventilation, and infection source other than urine (lung, abdomen,
line, central nervous system, skin). Variables pressors and severe sepsis were
excluded because of collinearity with septic shock. APACHE, Acute Physiology
and Chronic Health Evaluation; IAAT, initially appropriate antibiotic therapy. Area
under the receiver operating characteristics curve = 0.777; Hosmer–Lemeshow
P = 0.823.
Table 4 Predictors of receiving initially inappropriate
antibiotic therapya
Odds ratio 95% confidence
interval
P value
Multidrug resistant 13.05 7.00-24.31 <0.001




Nursing home resident 2.28 1.35-3.84 0.002
Prior antibiotics 2.06 1.47-2.87 <0.001
Polymicrobial 1.90 1.30-2.77 0.001
Congestive heart failure 1.61 1.11-2.35 0.013
APACHE II score (per 1 point) 1.05 1.02-1.07 <0.001
aIndependent variables included but not retained in the model at alpha ≤0.05:
age, admission source other than transfer from another hospital (home or
nursing home), comorbidities of chronic obstructive pulmonary disease, chronic
kidney disease, diabetes and malignancy, healthcare-associated infection risk
factors hemodialysis, immune suppression and prior hospitalization, prior
bacteremia, hospital length of stay prior to the onset of bacteremia, surgery,
central line, total parenteral nutrition, septic shock, and infection source. APACHE,
Acute Physiology and Chronic Health Evaluation. Area under the receiver
operating characteristics curve = 0.738, Hosmer–Lemeshow P = 0.664.
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Table 5 Baseline and infection characteristics
IAAT Non-IAAT P value
N % N %
819 76.97 245 23.03
Baseline characteristics
Age (years)
Mean ± standard deviation 60.3 ± 15.1 61.8 ± 15.1
Median (25th, 75th percentile) 62 (51, 71) 63 (52, 72) 0.165
Race
Caucasian 543 66.30 159 64.90 0.643
African-American 218 26.62 71 28.98
Hispanic 1 0.12 0 0.00
Other 9 1.10 0 0.00
Unknown 39 4.76 12 4.90
Asian 9 1.10 3 1.22
Sex, female 377 46.14 119 48.57 0.504
Admission source
Home 585 71.52 123 50.20 <0.001
Nursing home (including LTAC) 62 7.58 30 12.24
Transfer from other hospital 148 18.09 83 33.88
Unknown 20 2.44 8 3.27
Other 3 36.00 1 0.41
Comorbidities
CHF 150 18.32 64 26.12 0.009
COPD 190 23.30 73 29.80 0.043
CLD 134 16.36 36 14.69 0.619
DM 202 24.66 72 29.39 0.157
CKD 141 17.22 53 21.63 0.131
Malignancy 379 46.28 89 36.33 0.007
HIV 7 85.00 5 2.04 0.161
Charlson comorbidity score
Mean ± standard deviation 5.00 ± 3.35 5.18 ± 3.52
Median (25th, 75th percentile) 5 (2, 7) 4 (3, 8) 0.624
HCA risk factor
Hemodialysis 55 6.80 38 15.64 <0.001
Immune suppression 334 41.70 90 37.34 0.228
Prior hospitalization 485 62.26 164 71.30 0.012
Nursing home residence 62 7.57 30 12.24 0.022
Prior antibiotics 429 52.38 170 69.39 <0.001
Hospital-acquired BSIa 366 44.69 137 55.92 0.002
Prior bacteremia within 30 days 95 11.60 39 15.92 0.074
Sepsis characteristics
LOS prior to bacteremia (days)
Mean ± standard deviation 7.0 ± 12.1 11.7 ± 19.6
Median (25th, 75th percentile) 1 (0, 10) 5 (0, 16) <0.001
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24 hours of obtaining the blood culture. This informs
yet another corrective approach, one that requires sim-
ply to recognize the presence of a severe infection and
to institute empiric treatment in a timely manner. These
three mechanisms for exposure to non-IAAT and their
corrective strategies are subtly yet importantly different
from one another. In the current study we focus specif-
ically on the impact of multidrug resistance on the risk
of non-IAAT.
The prevalence of Gram-negative resistance has been
mounting over the last decade [4-6]. However, most
prior work describing the epidemiology of MDR Gram-
negative pathogens has focused on the prevalence of
resistance among specific species in specific infections.
For example, a recent study demonstrated that between
2000 and 2009 nationwide in the United States there
was a rise of MDR-PA from 10.7 to 13.5% in blood-
stream infections, and from 19.2 to 21.7% in pneumonia
[4]. The proportion of P. aeruginosa that met the MDR
definition in the current study (15.0%) is consistent with
these national estimates. The prevalence of carbapenem-
resistant Enterobacteriaceae that we report here is also
in line with national estimates [4-6]. In general, the simi-
larity of the overall prevalence of multidrug resistance in
our study to what has been reported nationally lends
external validity to our observations. Moreover, our study
is unique in its pragmatic perspective relevant to an ICU
clinician and focuses on a common syndrome that repre-
sents a final common pathway for several infection types.
Much research from the last decade has highlighted the
strong relationship between the choice of empiric anti-
microbial treatment and the risk of death among patients
hospitalized with serious infections. Most studies suggest
that the risk of hospital death in association with non-
IAAT goes up twofold to fourfold when compared with
patients who receive appropriate coverage [7-9,11-15].
Furthermore, switching from inappropriate to appropriate
coverage once the culture results have become available
Table 5 Baseline and infection characteristics (Continued)
Surgery
None 575 70.90 162 66.94 0.033
Abdominal 152 18.74 36 14.88
Extra-abdominal 84 10.36 44 18.18
Central line 491 62.31 170 72.34 0.005
TPN at time of bacteremia or prior to it during index hospitalization 53 6.59 22 9.17 0.175
APACHE II score
Mean ± standard deviation 16.5 ± 6.2 18.7 ± 6.6
Median (25th, 75th percentile) 16 (12, 20) 18 (14, 22) <0.001
Severe sepsis 451 55.07 108 44.08 0.003
Septic shock requiring pressors 368 44.93 137 55.92
On mechanical ventilation 176 21.57 89 36.33 <0.001
Peak WBC
Mean ± standard deviation 22.1 ± 18.3 22.9 ± 17.1
Median (25th, 75th percentile) 17.0 (7.5, 33.8) 18.3 (8.6, 37.0) 0.298
Infection sourceb
Urine 206 25.15 55 22.45 0.446
Abdomen 124 15.14 31 12.65 0.355
Lung 154 18.80 63 25.71 0.024
Line 87 10.62 22 8.98 0.548
CNS 6 0.73 1 0.41 1.000
Skin 41 5.01 21 8.57 0.043
Unknown 260 31.75 71 29.98 0.432
Polymicrobal BSI 130 15.87 59 24.08 0.003
MDR BSI 16 1.95 45 18.37 <0.001
aHospital-acquired BSI defined as BSI that developed after day 2 of hospitalization. bMultiple sources possible. APACHE, Acute Physiology and Chronic Health
Evaluation; BSI, bloodstream infection; CHF, congestive heart failure; CKD, chronic kidney disease; CLD, chronic liver disease; CNS, central nervous system; COPD,
chronic obstructive pulmonary disease; DM, diabetes mellitus; HCA, healthcare-associated; IAAT, initially appropriate antibiotic therapy; LOS, length of stay; LTAC,
long-term acute care; MDR, multidrug resistant; TPN, total parenteral nutrition; WBC, white blood cells.
Zilberberg et al. Critical Care 2014, 18:596 Page 9 of 13
http://ccforum.com/content/18/6/596
does not reduce the mortality risk imparted by this early
failure [10]. In this way our study adds to the understand-
ing of the importance of choosing appropriate empiric
treatment specifically to the outcomes of Gram-negative
sepsis, and extends this understanding to suggest not only
the mechanism for this finding, but also the contribution
of multidrug resistance to the risk of making this import-
ant error in early management.
The potential policy and public health implications of
our results are significant. Most attempts to improve
rates of IAAT have relied on a strategy of prompt admin-
istration of broad empiric coverage informed by the local
antibiogram, followed by de-escalation. In fact, this is the
strategy advocated by the Surviving Sepsis Campaign [16].
To prevent antibiotic abuse, the broad regimen is tailored
as culture data become available, and the shortest appro-
priate course of therapy is given. This paradigm suggests
that the way to address low rates of IAAT is to shift to
using broader spectrum agents such as anti-pseudomonal
carbapenems or ESBLs and/or chephalosporins. Unfortu-
nately, in the case of MDR Gram-negative organisms, this
is simply not an option. Few agents currently available
provide in vitro activity against MDR-PA and CPE. Those
agents that are available, such as colistin, carry important,
albeit somewhat controversial, safety concerns [22-25].
Simply selecting broader spectrum agents for the initial
therapy is therefore not an option, because the current
antibiotic armamentarium does not cover these MDR
organisms. This highlights why new agents are urgently
needed. As such, regulatory authorities and policy-makers
need to develop expedited pathways for antibiotic devel-
opment and approval. Such initiatives in the United States
as the Generating Antibiotic Incentives Now Act, which
provide incentives to support the development of newer
antibiotics, are to be lauded [26]. These efforts must
continue to be expanded and refined.
An additional point worth emphasizing is the relatively
low prevalence of MDR pathogens in our study, and the
implications of this for potential overuse of empiric
broad-spectrum antibiotics, if such are available. Al-
though certainly suboptimal with respect to both over-
use and increased resource utilization, at the moment
there is no way to tailor such therapies with any degree
of precision. Yet not administering appropriate coverage
results in a high penalty for the patient who is unlucky
enough to harbor a MDR organism, with a fourfold in-
crease in the risk of death. This situation underscores
the urgency of the need for development of faster diag-
nostic tools, as well as risk stratification algorithms that
may help clinicians to use broad-spectrum drugs ap-
propriately. At the moment, however, the only viable
solution appears to be to understand local resistance
patterns in real time and make therapeutic choices based
on them.
Table 6 Distribution of inappropriate treatment by
organism
IAAT Non-IAAT
N % N %
819 76.97 245 23.03
Pseudomonas aeruginosa 129 75.44 42 24.56
Acinetobacter spp. 19 26.03 54 73.97
Bacteroides spp. 51 63.75 29 36.25
Stenotrophomonas maltophilia 2 9.09 20 90.91
Enterobacteriaceae
Klebsiella pneumoniae 186 86.92 28 13.08
Escherichia coli 247 88.21 33 11.79
Klebsiella oxytoca 27 77.14 8 22.86
Proteus mirabilis 45 81.82 10 18.18
Serratia marcescens 39 84.78 7 15.22
Citrobacter freundii 22 88.00 3 12.00
Enterobacter aerogenes 29 82.86 6 17.14
Enterobacter cloacae 72 80.90 17 19.10
Polymicrobial 130 68.78 59 31.22
IAAT, initially appropriate antibiotic therapy.
Table 7 Predictors of receiving initially inappropriate
antibiotic therapya
Odds ratio 95% confidence
interval
P value
Stenotrophomonas maltophilia 91.981 20.538 to 411.956 <0.001
Multidrug resistant 23.045 12.097 to 43.900 <0.001
Acinetobacter spp. 17.410 9.600 to 31.574 <0.001
HIV 4.547 1.255 to 16.477 0.021
Bacteroides spp. 4.202 2.466 to 7.159 <0.001
Transfer from another hospital 2.280 1.527 to 3.403 <0.001
Polymicrobial 2.294 1.498 to 3.512 <0.001
Prior antibiotics 1.793 1.238 to 2.597 0.002
Congestive heart failure 1.683 1.097 to 2.582 0.017
APACHE II score 1.051 1.023 to 1.081 <0.001
aThis model includes all factors identified in the model in Table 4 with the
addition of the three pathogens with strikingly different initially appropriate
antibiotic therapy patterns identified in Table 6. Please note that all other
previously identified factors stayed in, except nursing home residence, which
fell out based on significance (lower bound of the 95% confidence interval
was 0.921). The area under the receiver operating characteristics curve is
improved compared with the model in Table 4. However, we feel that this
model does not add any clinical or policy utility when compared with the
original model. While the multidrug-resistant designation provides an
actionable data point with regard to stewardship and prevention of resistance
development, the other microbiology variables simply represent organisms
routinely isolated from septic patients. For this reason, we are offering this
alternate regression and retaining the original regression as a part of the main
manuscript. These data further emphasize the need for clinicians to know their
individual centers’ case mix vis-à-vis microorganisms associated with sepsis
and their predominant susceptibility patterns. APACHE, Acute Physiology and
Chronic Health Evaluation. Area under the receiver operating characteristics
curve = 0.827, Hosmer–Lemeshow P = 0.162.
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Our study has a number of limitations. As a retrospective
cohort it is prone to several forms of bias, most notably
selection bias. We attempted to mitigate this by enrolling
consecutive patients fitting the pre-determined enrollment
criteria. Although we dealt with confounders by adjusting
for those that were available, it is possible that some re-
sidual confounding remains. One specific potential residual
confounder is the type of surgery; that is, although we have
data on whether each patient either had a surgical proced-
ure or was cared for on a surgical service during his/her
hospitalization, we do not know whether the surgery was
related to the sepsis episode or was performed for infec-
tious source control. However, based on prior experience
at BJC, only a minority of patients is likely to have under-
gone source control surgery. The fact that this is a single-
center study in a very specific population of patients (those
with Gram-negative sepsis) may diminish the generali-
zability of our results to other centers and populations.
One important point is that Clinical Laboratory and
Standards Institute break-points for susceptibility changed
for some of the antibiotics during the study time frame
[19,20]. The lowering of these values almost certainly
resulted in an increase in the proportion of resistant organ-
isms. This likely increase, however, would dilute rather
than inflate the impact of multidrug resistance on the re-
ceipt of IAAT. Since we used only the susceptibility profile
and the timing of antibiotic administration as surrogates
for IAAT, our definition may have been overly liberal and
included some cases that would have been deemed non-
IAAT if other factors such as dosing and tissue penetration
had been examined. Another source of possible misclassi-
fication is our use of ICD-9-CM codes to identify organ
failures. While this identification may be less accurate than
clinical data, this methodology has been validated and
widely utilized in health services research [17]. The same
situation arose for comorbidities, thus eliminating the pos-
sibility of examining whether or how their severity may im-
pact the outcomes. Finally, because we examined hospital
mortality rather than the more standard 28-day mortality
as the primary outcome for our study, we may have under-
estimated the magnitude of this outcome.
Conclusions
In summary, our study provides evidence that once the
high risk of a serious infection has been recognized by a
clinician and empiric treatment for common pathogens
instituted, MDR organisms are an important factor in
determining the risk of non-IAAT, and, by extension,
hospital mortality in Gram-negative sepsis. Given the
paucity of currently available antimicrobial options to
cover this emerging threat, the key immediate solution
is their prevention through various protocols to address
ventilator and central venous catheter care, as well as
through antibiotic stewardship programs [27-29].
Definitions
 Septic shock: vasopressors (norepinephrine,
dopamine, epinephrine, phenylephrine, or
vasopressin) initiated within 24 hours of the blood
culture collection date and time.
 IAAT: initially prescribed antibiotic regimen active
against the identified pathogen based on in vitro
susceptibility testing and administered within
24 hours following blood culture collection.
 Prior antibiotic exposure: any exposure to an
antibiotic within the preceding 90 days.
 Prior hospitalization: any hospitalization within the
preceding 90 days.
 Prior bacteremia: a bacteremia episode within
30 days of the current episode.
 MDR-PA: a P. aeruginosa resistant to at least three




 MDR case: blood culture positive for a MDR-PA,
an ESBL organism or a CPE.
 Healthcare-associated infection: the presence of at
least one of the following risk factors: recent
hospitalization (within 90 days of the current one);
immune suppression; nursing home residence;
hemodialysis; and prior antibiotics (within 90 days
of the current hospitalization).
Key messages
 Among patients with severe sepsis/septic shock due
to a Gram-negative organism, initially inappropriate
antibiotic treatment is associated with a threefold
increase in hospital mortality.
 Multidrug resistance is strongly associated with
inappropriate treatment.
Abbreviations
CPE: carbapenemase-producing Enterobacteriaceae; ESBL: extended-spectrum
beta-lactamase; IAAT: initial appropriate antibiotic therapy; ICD-9-
CM: International Classification of Diseases, Version 9, Clinical Modification;
MDR: multidrug resistant; MDR-PA: multidrug-resistant Pseudomonas aeruginosa.
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